

REMARKS

Applicants have withdrawn claim(s) 10-27, 38-55, 59-63, as drawn to a non-elected invention. Applicant(s) respectfully request entry of this amendment.

In response to the Restriction Requirement, requiring election of one of Groups I - XII, Applicant(s) elect Group IX, drawn to methods wherein the NgR antagonist is a clostridium botulinum C3 ADP-ribosyltransferase encoded by DNA, without traverse. Claims 1-9, 28-37, 56-58 encompass the elected invention.

In response to the requirement of an election of species for an agent that activates the growth pathway of CNS neurons, Applicants elect CNTF. Claims 1-4, 7, 28-32, 35, 56-58 are readable thereon. Applicants note that if a generic claim is held to be allowable, claims to the non-elected species which depend from an allowable generic claim will be examined.

Applicants reserve the right to file continuing applications or take any such other appropriate action as deemed necessary to protect the non-elected inventions. Applicants do not hereby abandon or waive any rights in the non-elected inventions.

Applicants respectfully submit that all claims are in condition for allowance. Entry of the foregoing and prompt and favorable consideration of the subject application on the merits are respectfully requested.

Fee deficiencies may be charged and overpayments credited to the NIXON PEABODY LLP Deposit Account No. 50-0850.

Date: July 13, 2009

Respectfully submitted,

Customer No.: 50828

/Shayne Y. Huff/

David S. Resnick (Reg. No. 34,235)
Shayne Y. Huff (Reg. No. 44,784)
NIXON PEABODY LLP
100 Summer Street
Boston, MA 02110
Tel. (617) 345-1000
Fax (617) 345-1300
E-mail: bostonpatent@nixonpeabody.com